Overview

* Ionis Q2 2025 revenue doubles yr/yr, beating analyst expectations

* Adjusted operating income beats expectations, driven by TRYNGOLZA launch

* Co raises 2025 financial guidance, citing improved outlook and performance

Outlook

* Ionis raises 2025 revenue guidance to $825-850 mln

* Company expects TRYNGOLZA sales of $75-80 mln in 2025

* Ionis anticipates sustained growth and positive cash flow

*

Result Drivers

* TRYNGOLZA LAUNCH - Strong revenue growth driven by TRYNGOLZA's successful launch, generating $19 mln in Q2 sales

* ROYALTY REVENUE - Increased royalty revenue from products like SPINRAZA and WAINUA contributed to revenue growth

* COMMERCIAL INVESTMENTS - Operating expenses rose due to investments in commercializing TRYNGOLZA, donidalorsen, and WAINUA

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $452 mln $295.20

Revenue mln (19

Analysts

)

Q2 Net $124 mln

Income

Q2 Beat $170 mln -$44.90

Adjusted mln (12

Operatin Analysts

g Income )

Q2 $282 mln

Adjusted

Operatin

g

Expenses

Q2 $312 mln

Operatin

g

Expenses

Q2 $140 mln

Operatin

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 8 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Ionis Pharmaceuticals Inc ( IONS ) is $58.00, about 28.5% above its July 29 closing price of $41.48

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)